Cost-Effectiveness of an Adjuvanted Hepatitis B Vaccine (HEPLISAV-B) in Patients With Inflammatory Bowel Disease

Abstract Background Compare the cost-effectiveness of 2 recombinant hepatitis B virus (HBV) vaccines in patients with inflammatory bowel disease (IBD). Methods Markov models were developed for 2 IBD cohorts: (1) 40-year-old patients prior to starting IBD treatment and (2) 40-year-old patients alread...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Crohn's & Colitis 360 2021-01, Vol.3 (1), p.otaa090
Hauptverfasser:	Corral, Juan E, Kwon, Joshua Y, Caldera, Freddy, Pungpapong, Surakit, Spaulding, Aaron C, Borah, Bijan J, Moriarty, James P, Farraye, Francis A
Format:	Artikel
Sprache:	eng
Schlagworte:	Crohn's disease Development and progression Economic aspects Hepatitis B Hepatitis B vaccine Liver cirrhosis Markov processes Type 2 diabetes Ulcerative colitis Vaccination
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!